Results 21 to 30 of about 165,686 (209)

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit

Frontiers in Pediatrics, 2022
ObjectiveTo explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding ...
Bo Zhou, Bo Zhou, Bo Zhou, Bo Zhou, Wenyi Xiong, Ke Bai, Ke Bai, Ke Bai, Ke Bai, Hongxing Dang, Hongxing Dang, Hongxing Dang, Hongxing Dang, Jing Li, Jing Li, Jing Li, Jing Li, Feng Xu, Feng Xu, Feng Xu, Feng Xu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Chengjun Liu, Chengjun Liu, Chengjun Liu, Chengjun Liu   +28 more
doaj   +1 more source

Vancomycin: A History [PDF]

Clinical Infectious Diseases, 2006
Vancomycin became available for clinical use >50 years ago but was soon discarded in favor of other antibiotics that were deemed to be more efficacious and less toxic. The advent of pseudomembranous enterocolitis, coupled with the spread of methicillin-resistant Staphylococcus aureus, led to a resurgence in the use of vancomycin.
openaire   +2 more sources

Vancomycin-Resistant Enterococcus faecalis (VRE) control assay after 3 min exposure to 1% w/v Bioxy in neutralizer. [PDF]

, 2017
Vancomycin-Resistant Enterococcus faecalis (VRE) control assay after 3 min exposure to 1% w/v Bioxy in neutralizer.
Ken Ungar (3753265), Richard Robison (69760), Dori Dagher (3753271), Fadi Dagher (3753268)   +3 more
core   +1 more source

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

International Journal of Pediatrics, 2018
Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been ...
Mohammed Al Nuhait, Laila C. Abu Esba, Khalid Al Harbi, Meshary Al Meshary, Rami T. Bustami   +4 more
doaj   +1 more source

Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections

Frontiers in Pharmacology, 2022
Objective: The decision of vancomycin dosage for central nervous system (CNS) infections is still a challenge because its bactericidal nature in cerebrospinal fluid (CSF) has not been confirmed by human studies.
Shu-Ping Liu, Jing Xiao, Ya-Li Liu, Yue-E Wu, Hui Qi, Zhuang-Zhuang Wang, A-Dong Shen, A-Dong Shen, Gang Liu, Wei Zhao, Wei Zhao   +10 more
doaj   +1 more source

Bacteriocin Production in Vancomycin-Resistant and Vancomycin-Susceptible Enterococcus Isolates of Different Origins [PDF]

, 2001
Bacteriocin production was determined for 218 Enterococcus isolates (Enterococcus faecalis [93] and E. faecium [125]) obtained from different origins (human clinical samples [87], human fecal samples [78], sewage [28], and chicken samples [25]) and ...
Jiménez Díaz, Rufino, Torres, Carmen, Rubio, Carmen, Rafael Gómez-Lus, Gómez-Lus, R., Baquero, F., Tenorio, Carmen, Carmen Torres, Carmen Rubio, Baquero, Fernando, Tenorio, C. [0000-0002-8099-1208], Rubio, C., Carmen Tenorio, Rufino Jiménez-Dı́az, Gómez-Lus, Rafael, Torres, C. [0000-0003-3709-1690], Fernando Baquero, Jiménez-Díaz, R. [0000-0001-7881-511X], Campo, Rosa del, Rosa Del Campo, Del Campo, R. [0000-0003-1147-7923]   +20 more
core   +1 more source

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci

Brazilian Journal of Infectious Diseases, 2015
Background: Vancomycin-resistant enterococci colonization has been reported to increase the risk of developing infections, including bloodstream infections.
Ahu Kara, İlker Devrim, Nuri Bayram, Nagehan Katipoğlu, Ezgi Kıran, Yeliz Oruç, Nevbahar Demiray, Hurşit Apa, Gamze Gülfidan   +8 more
doaj   +1 more source

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Journal of Infection and Public Health, 2022
Background: Therapeutic drug monitoring (TDM) has proven effectiveness in maintaining efficacy and reducing toxicities associated with vancomycin. A trough level of (15–20 mg/L) for MRSA serious infections is recommended.
Juhaina Salim Al-Maqbali, Zahra Al Shukri, Nawf Al Sabahi, Intisar AL-Riyami, Abdullah M. Al Alawi   +4 more
doaj   +1 more source

Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

Microbiology Spectrum
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures.
Ji Hyun Yun, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim   +9 more
doaj   +1 more source

Parenterally administered vancomycin in 29 dogs and 7 cats (2003‐2017)

Journal of Veterinary Internal Medicine, 2019
Background Vancomycin is commonly used to treat resistant bacterial infections in people. Reported adverse effects of vancomycin in people include acute kidney injury (AKI), neutropenia, and systemic allergic reaction.
Ian M. DeStefano, Annie S. Wayne, Elizabeth A. Rozanski, Jonathan M. Babyak   +3 more
doaj   +1 more source